|
業務類別
|
Drug Manufacturers - Specialty & Generic |
|
業務概覽
|
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species. |
| 公司地址
| 1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548 |
| 電話號碼
| +1 201 884-5485 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.scynexis.com |
| 員工數量
| 28 |
| Mr. Scott Sukenick |
Chief Legal Officer and General Counsel |
美元 442.27K |
30/04/2025 |
| Dr. David Angulo, M.D. |
Chief Executive Officer, President and Director |
美元 595.33K |
04/03/2026 |
| Mr. Ivor Macleod, C.P.A.,M.B.A. |
Chief Financial Officer and Principal Accounting Officer |
美元 449.50K |
04/03/2026 |
|
|
| Dr. Ann F. Hanham,PhD |
Independent Director |
04/03/2026 |
| Mr. Brian Philippe Tinmouth |
Independent Director |
04/03/2026 |
| Dr. David Angulo, M.D. |
Chief Executive Officer, President and Director |
04/03/2026 |
| Mr. David C. Hastings |
Independent Director |
04/03/2026 |
| Mr. Armando Anido |
Independent Director |
04/03/2026 |
| Dr. Steven C. Gilman, PhD |
Independent Director |
04/03/2026 |
| Mr. Guy Macdonald |
Chairman of the Board |
04/03/2026 |
|
|
|
|
